A designed TLR4/MD-2 complex to capture LPS

Abstract

The family of Toll-like receptors (TLRs) is involved in the defense of an organism to microbial attack. TLR4-induced signaling is involved in infectious diseases, chronic inflammatory diseases and sepsis; therefore, we aimed at modulating TLR4-signaling via ligand-binding soluble receptors. Because recognition of microbial structures shows some species-specific traits, we specifically selected the mouse model for later in vivo studies. We first prepared the N-terminally Flag-tagged mouse (m) recombinant (r) soluble (s) fusion proteins mrsTLR4-IgGFc (T4Fc) and mrsMD-2 in Drosophila melanogaster Schneider 2 (S2) cells. The function of these molecules was tested by inhibition of synthesis of pro-inflammatory cytokines after stimulation of mouse macrophage RAW 264.7 cells with purified lipopolysaccharide (LPS). T4Fc alone had no inhibitory activity; however, a T4Fc/MD-2 complex blocked LPS activity. By analogy with `cytokine traps', we then prepared a designer molecule (LPS-Trap) by fusing MD-2 to the C-terminus of soluble TLR4 via a flexible linker. LPS-Trap significantly inhibited TNF production by LPS-stimulated RAW 264.7 cells. Thus, the T4Fc/MD-2 complex as well as the LPS-Trap blocked LPS activity in vitro and might thus represent a new therapeutic option in sepsis by neutralization of TLR4-activating ligands.

Keywords

Designer molecule LPS MD-2 signaling soluble TLR4

References

Angus DC , Linde-Zwirble WT , Lidicker J. , Clermont G. , Carcillo J. , Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303—1310.

Medzhitov R. , Preston-Hurlburt P. , Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity . Nature 1997; 388: 394—397.

Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling . Nature 2004; 430: 257—263.

Abreu MT , Arditi M. Innate immunity and Toll-like receptors: clinical implications of basic science research. J Pediatr 2004; 144: 421—429.

Zhang D. , Zhang G. , Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303: 1522—1526.

Dunne A. , O'Neill LA The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3.

Janeway Jr CA , Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197—216.

Beutler B. Innate immunity: an overview. Mol Immunol 2004; 40: 845—859.

Ingalls RR , Heine H. , Lien E. , Yoshimura A. , Golenbock D. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect Dis Clin North Am 1999; 13: 341—353, vii.

10.

Nagai Y. , Akashi S. , Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution . Nat Immunol 2002; 3: 667—672.

11.

Schromm AB , Lien E. , Henneke P. et al. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD2 abolishes endotoxin-induced signaling. J Exp Med 2001; 194: 79—88.

12.

Shimazu R. , Akashi S. , Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777—1782.

13.

Thompson PA , Tobias PS , Viriyakosol S. , Kirkland TN , Kitchens RL Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003 ; 278: 28367—28371.

14.

Fujimoto T. , Yamazaki S. , Eto-Kimura A. , Takeshige K. , Muta T. The amino-terminal region of Toll-like receptor 4 is essential for binding to MD-2 and receptor translocation to the cell surface. J Biol Chem 2004; 279: 47431—47437.

15.

Heaney ML , Golde DW Soluble cytokine receptors. Blood 1996; 87: 847—857.

16.

Iwami KI , Matsuguchi T. , Masuda A. , Kikuchi T. , Musikacharoen T. , Yoshikai Y. Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165: 6682—6686.

17.

Hyakushima N. , Mitsuzawa H. , Nishitani C. et al. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol 2004; 173: 6949—6954.

18.

Ancey C. , Kuster A. , Haan S. , Herrmann A. , Heinrich PC , Muller-Newen G. A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor. J Biol Chem 2003; 278: 16968—16972.

19.

Economides AN , Carpenter LR , Rudge JS et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9: 47—52.

20.

Ozinsky A. , Smith KD , Hume D. , Underhill DM Co-operative induction of proinflammatory signaling by Toll-like receptors . J Endotoxin Res 2000; 6: 393—396.

21.

Re F. , Strominger JL Monomeric recombinant MD-2 binds Toll-like receptor 4 tightly and confers lipopolysaccharide responsiveness. J Biol Chem 2002; 277: 23427—23432.

22.

Visintin A. , Latz E. , Monks BG , Espevik T. , Golenbock DT Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction . J Biol Chem 2003; 278: 48313—48320.

23.

Kennedy MN , Mullen GE , Leifer CA et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004; 279: 34698—34704.

24.

Akashi S. , Shimazu R. , Ogata H. et al. Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 2000; 164: 3471—3475.

25.

Picard C. , Puel A. , Bonnet M. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency . Science 2003; 299: 2076—2079.

26.

Medvedev AE , Lentschat A. , Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003; 198: 521—531.

27.

O'Brien AD , Rosenstreich DL , Scher I. , Campbell GH , MacDermott RP , Formal SB Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol 1980; 124: 20—24.

28.

O'Brien AD , Weinstein DA , Soliman MY , Rosenstreich DL Additional evidence that the Lps gene locus regulates natural resistance to S. typhimurium in mice. J Immunol 1985; 134: 2820—2823.

29.

Hoshino K. , Takeuchi O. , Kawai T. et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749—3752.

30.

Qureshi ST , Medzhitov R. Toll-like receptors and their role in experimental models of microbial infection . Genes Immun 2003; 4: 87—94.

31.

Reinhart K. , Gluck T. , Ligtenberg J. et al. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004; 32: 1100—1108.

32.

Opal SM , Gluck T. Endotoxin as a drug target. Crit Care Med 2003; 31: S57—S64.

33.

Meng G. , Rutz M. , Schiemann M. et al. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004; 113: 1473—1481.

34.

LeBouder E. , Rey-Nores JE , Rushmere NK et al. Soluble forms of Toll-like receptor (TLR)-2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171: 6680—6689.

35.

36.

Kennedy MN , Mullen GE , Leifer CA et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004; 33: 34698—34704.

37.

Visintin A. , Mazzoni A. , Spitzer JA , Segal DM Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA 2001; 98: 12156—12161.

38.

Viriyakosol S. , Kirkland T. , Soldau K. , Tobias P. MD-2 binds to bacterial lipopolysaccharide . J Endotoxin Res 2000; 6: 489—491.

39.

Ozbek S. , Peters M. , Breuhahn K. et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001; 20: 972—979.

40.

Peters M. , Blinn G. , Solem F. , Fischer M. , Meyer zum Buschenfelde KH , Rose-John S. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 1998; 161: 3575—3581.